CRP and hepatocellular carcinoma: In consideration of these factors, it is plausible that including hematological parameters like CRP and AFP, indicators of systemic inflammation and HCC biology respectively, in clinical staging evaluations may offer substantial aid in enhancing patient prognostic assessment and treatment allocation.